| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$20.7M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $559,394 | Trading Days | 608 |
| 52W High | 8.90 |
| 52W Low | 0.01 |
| % Off High | −99.86% |
| YTD | −81.49% | 1Y | −99.83% |
| Since incept. (ann.) | −99.61% |
| Ann. Volatility (1Y) | 202.13% | Ann. Volatility (3Y) | 254.73% |
| Sharpe (1Y) | −1.48 | Sharpe (3Y) | −1.00 |
| Max Drawdown (1Y) | −99.91% | Max Drawdown (3Y) | −100.00% |
| Beta (3Y, vs SPY) | 2.00 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VIVS | VivoSim Labs, INC. | $1.3M | — |
| PHGE | BiomX Inc. | $1.9M | 0.0 |
| CLDI | Calidi Biotherapeutics, Inc. | $2.1M | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $2.4M | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $2.7M | — |
| APTOF | Aptose Biosciences Inc. | $4.3M | — |
| LIMN | Liminatus Pharma, Inc. | $4.7M | — |
| PMCB | PharmaCyte Biotech, Inc. | $6.3M | 0.2 |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.9M | — |
| CVM | CEL SCI CORP | $10.2M | — |
| INAB | IN8BIO, INC. | $10.9M |
| INTS | INTENSITY THERAPEUTICS, INC. | $12.3M | — |
